Emcure cuts weight reduction drug price by 47%

Emcure Pharmaceuticals Ltd said it has decided to reduce the price of its weight management drug, Poviztra (semaglutide injection), effective April 3, 2026 to improve accessibility to essential weight-management therapies.

Now the starting dose of Poviztra (0.25 mg) will now be available at Rs. 3,999 per month (inclusive of taxes), a reduction of 55% from the previous price of Rs. 8,790, the company said.

Across all doses, the price of Poviztra has been reduced by an average of 47%. The drug is offered in five strengths: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and a maintenance dose of 2.4 mg.

Poviztra is the second brand of Novo Nordisk’s semaglutide injection for obesity and will be exclusively distributed and commercialized by Emcure Pharma in India.

“The price revision aims to make this clinically proven therapy more accessible to a larger patient base as India confronts a growing obesity epidemic,” the company said.

Satish Mehta, CEO and Managing Director, Emcure Pharmaceuticals, said, “This price revision is a vital step towards addressing the obesity epidemic in India, with nearly 254 million people living with generalized obesity.”

“The reduced pricing will support our ongoing commitment to improving health outcomes and increasing access to scientifically validated weight-management therapies,” he added.